Thermo Fisher Scientific (TMO) — Company Research
Last Updated: 17 July 2026
Thermo Fisher Scientific is the world's largest life-sciences tools and services company, supplying instruments, reagents, consumables, software and outsourced services to pharmaceutical, biotech, academic, government, clinical and industrial customers. The company reported full-year 2025 revenue of $44.56bn and adjusted EPS of $22.87, and lifted its 2026 outlook after a first quarter that beat expectations. With roughly $45bn of remaining performance obligations in its biopharma-services backlog, a serial acquisition model that most recently added clinical-trial data specialist Clario, and a large recurring consumables base, Thermo Fisher sits at the centre of the global research and drug-development economy. This report walks through the company's structure, financial health, valuation and the debate between bulls and bears. For live pricing see our Live Charts and upcoming catalysts on the Economic Calendar.
1. Company Snapshot
| Field | Value |
|---|---|
| Company | Thermo Fisher Scientific Inc. |
| Ticker / Exchange | TMO (NYSE) |
| Sector | Healthcare — Life Sciences Tools & Services |
| CEO / Leadership | Marc N. Casper (Chairman, President & Chief Executive Officer) |
| Employees | ~125,000 (as of 31 Dec 2025) |
| Headquarters | Waltham, Massachusetts, USA |
| Market cap | ~$196bn (14 Jul 2026) |
| Share price | ~$535 (mid-Jul 2026) |
| Revenue (FY2025) | $44.56bn |
| GAAP diluted EPS (FY2025) | $17.74 |
| Adjusted EPS (FY2025) | $22.87 |
| Dividend / share (FY2025 declared) | $1.72 |
| Next earnings | 23 Jul 2026 (Q2 2026) |
2. Bull vs Bear
Bull Case
- Unrivalled scale and breadth: At $44.6bn of revenue across four segments, Thermo Fisher is the largest company in life-sciences tools, giving it distribution reach, cross-selling and purchasing power that smaller rivals cannot match.
- Recurring, consumables-led revenue: A large share of sales comes from reagents, consumables and services that customers reorder continuously, producing a razor/razor-blade model with pricing power and visibility, backed by roughly $45bn of biopharma-services performance obligations.
- Proven M&A compounding: Management has a long record of accretive acquisitions; the $8.9bn Clario deal (closed March 2026) adds clinical-trial endpoint data, and the company still lifted 2026 guidance after folding it in.
- Strong cash generation and returns: Free cash flow of roughly $6.3bn in 2025 funded about $3.6bn of dividends and buybacks alongside continued M&A, supporting a self-reinforcing capital-allocation engine.
- Secular demand tailwinds: Long-run growth in biologics, cell and gene therapy, diagnostics and bioproduction underpins the addressable market as the post-COVID normalisation runs its course.
Bear Case
- Soft organic growth: Organic revenue rose only about 1% in Q1 2026; headline growth is leaning heavily on acquisitions and currency rather than underlying volume.
- Funding and policy pressure: Exposure to academic and government research budgets (including NIH funding scrutiny) and to China leaves a meaningful slice of demand vulnerable to policy shifts.
- Rising debt load: Total borrowings climbed toward roughly $43bn after the Clario financing, increasing interest cost and reducing balance-sheet flexibility.
- Wide GAAP-to-adjusted gap: GAAP EPS of $17.74 sits well below adjusted EPS of $22.87, largely because of about $1.7bn of annual intangible amortisation tied to past deals.
- Cyclical end-market risk: Pharma and biotech capital-equipment spending is cyclical, and tariff or trade-policy disruption could pressure both cost and demand.
3. Business Segments
Thermo Fisher reports in four segments. Segment revenues below are gross of intersegment eliminations of roughly $2.0bn, which reconcile to consolidated revenue of $44.56bn.
| Segment | % of revenue | What it is |
|---|---|---|
| Laboratory Products & Biopharma Services | ~52% ($23.98bn) | Lab equipment, consumables, channel/distribution, plus pharma services (CDMO, clinical trial logistics, the former PPD clinical-research business) |
| Life Sciences Solutions | ~22% ($10.37bn) | Reagents, instruments and consumables for biological research, genetic analysis and bioproduction |
| Analytical Instruments | ~16% ($7.55bn) | Mass spectrometry, chromatography, electron microscopy and chemical-analysis instruments and software |
| Specialty Diagnostics | ~10% ($4.68bn) | Clinical diagnostics reagents, immunodiagnostics, microbiology, transplant and allergy testing |
4. Business Model & Moat
How it makes money. The company sells a mix of one-off capital equipment (instruments) and high-margin recurring items (reagents, consumables, service contracts and outsourced pharma services). The recurring base is the profit engine: once an instrument or workflow is embedded in a lab, the customer keeps buying matched consumables and services for years, producing sticky, repeatable revenue.
Why the moat is durable. Switching costs are high because instruments, software, validated methods and regulatory sign-offs are difficult to change once a lab is running. Scale gives Thermo Fisher the widest catalogue and distribution network in the industry, and its balance sheet lets it acquire and integrate targets faster than peers. Brand trust in regulated clinical and pharmaceutical settings reinforces the position.
Where it is vulnerable. The moat is weaker in commoditised lab supplies and in instrument categories where Danaher, Agilent, Waters and Bruker compete hard on performance. Demand tied to research grants and pharma capital budgets can soften quickly in a downturn.
5. Financial Health
All figures below are drawn from Thermo Fisher's SEC filings (10-K, 10-Q) and quarterly earnings press releases. Revenue is on the company's reported basis.
| Fiscal Year | Revenue ($m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt ($m, YE) |
|---|---|---|---|---|---|---|
| FY2021 | 39,211 | +21.7% | $19.46 | $25.13 | $1.04 | 34,670 |
| FY2022 | 44,915 | +14.5% | $17.63 | $23.24 | $1.20 | 34,278 |
| FY2023 | 42,857 | −4.6% | $15.45 | $21.55 | $1.40 | 34,727 |
| FY2024 | 42,879 | +0.1% | $16.53 | $21.86 | $1.56 | 31,072 |
| FY2025 | 44,556 | +3.9% | $17.74 | $22.87 | $1.72 | 39,172 |
Quarterly detail (most recent first). GAAP EPS for Q4 2025 is derived by subtracting the first three reported quarters from the full-year figure.
| Quarter | Revenue ($m) | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q1 2026 | 11,005 | $5.44 | $4.43 |
| Q4 2025 | 12,215 | $6.57 | $5.21 |
| Q3 2025 | 11,122 | $5.79 | $4.27 |
| Q2 2025 | 10,855 | $5.36 | $4.28 |
| FY2025 total | 44,556 | $22.87 | $17.74 |
The balance sheet carried about $39.2bn of non-current long-term debt plus $3.5bn of current debt at year-end 2025, against roughly $9.9bn of cash and $0.3bn of short-term investments. Operating cash flow was $7.82bn and capital expenditure $1.53bn, giving free cash flow of about $6.3bn.
6. Valuation
Raw metrics, July 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$196bn (14 Jul 2026) |
| Enterprise value | ~$229bn (market cap ~$196bn + total debt ~$42.7bn − cash & ST investments ~$10.1bn per FY2025 balance sheet) |
| Trailing P/E (GAAP) | ~29x (price ~$535 / TTM GAAP EPS ~$18.19, i.e. FY2025 $17.74 − Q1 2025 $3.98 + Q1 2026 $4.43) |
| P/E (forward) | ~21.5x (price ~$535 / FY2026 adjusted EPS guidance midpoint ~$24.88) |
| P/S (TTM) | ~4.3x (market cap ~$196bn / TTM revenue ~$45.2bn) |
| EV/EBITDA (TTM) | ~22x (EV ~$229bn / FY2025 EBITDA ~$10.5bn; EBITDA = operating income $7.75bn + D&A $2.78bn per cash flow statement) |
| P/FCF | ~31x (market cap ~$196bn / FCF ~$6.3bn; FCF = operating cash flow $7.82bn − capex $1.53bn per FY2025 cash flow statement) |
| 52-week high | $643.99 |
| 52-week low | $385.46 |
| Short interest (% of float) | ~1.0% (Benzinga, latest 2026 reading; ~3.9m shares) |
| Days to cover | ~2.8 days |
7. What Are They Building
Thermo Fisher's growth roadmap runs along three lines: acquisitions, capacity and innovation. The largest recent move is the $8.875bn purchase of Clario, closed in March 2026, which bolts clinical-trial endpoint data and decentralised-trial technology onto the existing pharma-services franchise and deepens the company's role across the drug-development lifecycle. Alongside deals, the company continues to invest in bioproduction and pharma-services capacity to serve biologics and cell-and-gene-therapy manufacturing.
On the innovation side, Thermo Fisher used ASMS 2026 and BIO International 2026 to showcase next-generation mass spectrometry, AI-enabled research tools and manufacturing and clinical-development capabilities. It has also expanded forensic and mRNA partnerships, including regulatory clearance of its RapidINTEL Plus DNA cartridge for the FBI's national DNA index and a collaboration with Arcturus Therapeutics to support Phase 3 development of an mRNA cystic-fibrosis therapy. The through-line is embedding Thermo Fisher deeper into regulated, recurring-revenue workflows.
8. Peer Comparison
| Peer | Market cap (Jul 2026) | Key 2025 metric |
|---|---|---|
| Thermo Fisher (TMO) | ~$196bn | FY2025 revenue $44.56bn |
| Danaher (DHR) | ~$141bn | FY2025 revenue $24.6bn |
| Agilent Technologies (A) | ~$37bn | FY2025 (Oct) revenue $6.95bn |
| Waters (WAT) | ~$37bn | FY2025 revenue $3.17bn |
| Revvity (RVTY) | ~$12bn | FY2025 revenue $2.86bn |
9. Insider Activity
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Marc N. Casper (Chairman & CEO) | 05 Mar 2026 | Sale | ~4,000 | $503.66–$519.74 | ~$2.06m | Rule 10b5-1 |
| Marc N. Casper (Chairman & CEO) | 03–04 Mar 2026 | Option exercise & sale | 10,000 | exercise $309.63 | — | Rule 10b5-1 |
| Marc N. Casper (Chairman & CEO) | 28 Aug 2025 | Sale | ~1,411 | $489.74 | ~$0.69m | Open market |
Recent insider activity has been routine sales and option exercises by the CEO under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025, rather than open-market conviction buying or selling. No material insider purchases were reported in the period.
10. Key Risks
- Research-funding and policy risk (Regulatory/Macro): Cuts or delays to academic and government research budgets, including NIH funding pressure, could reduce demand across multiple segments.
- China and geopolitical exposure (Macro): A meaningful revenue slice is tied to China and to global trade; tariffs or restrictions could hit both demand and cost.
- Leverage and interest cost (Financial): Total borrowings near $43bn after the Clario financing raise interest expense and constrain flexibility if cash flow softens.
- Integration and M&A execution (Operational): The growth model depends on repeatedly integrating large acquisitions; a misstep on Clario or a future deal could dilute returns.
- End-market cyclicality (Operational): Pharma and biotech capital-equipment spending is cyclical and can weaken faster than the recurring base can offset.
- Competitive intensity (Operational): Danaher, Agilent, Waters, Bruker and others compete aggressively on instrument performance and price in overlapping categories.
- Currency translation (Macro): A large international footprint means reported revenue and earnings are sensitive to a stronger US dollar.
11. Recent Developments
- 01 Jul 2026 — Dividend, forensics clearance and mRNA partnership. The board declared a quarterly dividend of $0.47; the RapidINTEL Plus DNA cartridge was approved for the FBI's national DNA index; and Thermo Fisher joined Arcturus Therapeutics to support Phase 3 development of an mRNA cystic-fibrosis therapy.
- 23 Apr 2026 — Q1 2026 results beat and guidance raised. Revenue rose 6% to $11.01bn with adjusted EPS of $5.44 and GAAP EPS of $4.43; management raised full-year revenue guidance to $47.3–$48.1bn and adjusted EPS to $24.64–$25.12, reflecting Clario.
- 24 Mar 2026 — Clario acquisition completed. Thermo Fisher closed the $8.875bn cash purchase of clinical-trial data firm Clario, expanding its clinical-development capabilities.
- 29 Jan 2026 — Q4 and full-year 2025 results. Full-year revenue grew 4% to $44.56bn with adjusted EPS up 5% to $22.87; Q4 revenue was $12.2bn and Q4 adjusted EPS $6.57.
- 29 Oct 2025 — Clario deal announced. The company agreed to acquire Clario for about $8.9bn in cash, plus performance-based payments.
12. Key Dates
- 23 Jul 2026 — Q2 2026 results before market open, with conference call at 8:30 a.m. ET
- 15 Oct 2026 — expected Q3 2026 results (provisional, based on prior-year cadence)
- 28 Jan 2027 — expected Q4 and full-year 2026 results (provisional)
For scheduled market-moving events and earnings, keep an eye on the ChartsView Economic Calendar, and discuss ideas on the Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Loading research report…
13. Thesis Verdict
The central thesis. Thermo Fisher Scientific is the world's largest life-sciences tools and services company, earning most of its money from recurring reagents, consumables and outsourced pharma services layered on an installed base of instruments. Full-year 2025 revenue rose 4% to $44.56bn with adjusted EPS of $22.87 and GAAP EPS of $17.74, and after a first-quarter 2026 beat management raised full-year guidance to $47.3–$48.1bn of revenue and $24.64–$25.12 of adjusted EPS. The primary structural driver is continued acquisition-led expansion — most recently the $8.9bn Clario deal — feeding a sticky, high-margin recurring-revenue base.
What would confirm or break it. Confirmation would come from the 23 July 2026 Q2 report landing in line with or above raised guidance and organic growth reaccelerating beyond the roughly 1% seen in Q1. The thesis weakens if research-funding and policy pressure or China exposure erodes demand, if the roughly $43bn debt load and integration of Clario strain returns, or if the persistent gap between GAAP and adjusted earnings signals deteriorating deal economics.
Watchpoints
- ConfirmsQ2 2026 earnings (6 days) landing in line with or above management guidance.
- ConfirmsEvidence supporting the "Unrivalled scale and breadth:" thesis continuing to build across subsequent filings.
- InvalidatesMaterialisation of the "Research-funding and policy risk (Regulatory/Macro):" risk, or any disclosure that fundamentally alters the capital-return or growth profile stated by management.
Diagnostic grid
Generated by ChartsView research tooling. Thesis strength measures how well the evidence in this report supports the company's stated thesis — it is NOT a buy/sell rating or price target. ChartsView is not authorised by the FCA to provide regulated investment advice. Generated 17 Jul 2026.